Standard of Care: Bile Acid Replacement Therapy
At a Glance
For children with CBAS1, prescribed cholic acid is the standard treatment because it replaces needed bile acids and helps stop toxic bile-acid buildup. Regular liver tests and vitamin A, D, E, and K monitoring are essential, and doses should never be changed without the specialist.
Because CBAS1 (HSD3B7 deficiency) is caused by a specific missing enzyme, it has a targeted treatment. This therapy does not just manage symptoms; it addresses the core biological failure of the disease [1]. For many children, this treatment allows the liver to function more normally and supports healthy growth and development [2].
The Standard of Care: Cholic Acid Therapy
The primary treatment for CBAS1 is oral cholic acid (brand name Cholbam). Cholic acid is a “primary” bile acid—the kind your child’s liver cannot make on its own [3].
This medication works in two vital ways:
- Suppression: It sends a signal to the liver to “stop” trying to make bile acids. This prevents the buildup of the toxic, abnormal intermediates that cause liver damage [4][5].
- Replacement: It provides the bile acids necessary to absorb fats and fat-soluble vitamins from food, which are essential for brain development, bone health, and proper blood clotting [6][7].
Dosing and Administration
Your child’s medical team will prescribe the dose based on their weight and the specific product label. In clinical studies, a common starting range is 10 to 15 mg/kg of body weight per day [5][8].
Important Administration Guidelines:
- Always take cholic acid strictly as directed by your specialist. Do not adjust the dose independently.
- It is generally administered with food.
- Ask your pharmacist exactly how to handle capsules or granules for an infant (e.g., whether they can be opened or mixed, and what not to crush or chew).
- Ask your team for written instructions on what to do if a dose is vomited or missed, and do not compensate for a missed dose unless instructed.
- Certain other medications (like bile-acid-binding resins or antacids) can interfere with absorption; review all medications with your pharmacist.
Monitoring and Vitamin Support
Because of malabsorption, your child will likely need extra help getting nutrients.
- Individualized Vitamin Supplementation: Your specialist will prescribe specific, often water-miscible, formulations of vitamins A, D, E, and K [6][8]. Do not start, stop, or change doses of over-the-counter supplements yourself. Fat-soluble vitamins can accumulate and cause toxicity (especially A and D).
- Ongoing Checks: Your specialist will regularly check blood levels of these vitamins and monitor PT/INR (a clotting test used to assess Vitamin K status) [8][9]. Improved bile-acid absorption does not guarantee that supplementation can be stopped.
Potential Side Effects and Precautions
While many children tolerate cholic acid well over long periods, it requires careful oversight [1]:
- Gastrointestinal Issues: Some children may experience diarrhea, nausea, or stomach pain [6].
- Advanced Liver Disease: If a child already has significant liver scarring (cirrhosis), doctors must use extreme caution. In advanced disease, cholic acid can sometimes cause liver markers to rise, indicating liver stress [10].
- Mandatory Lab Work: It is vital to never skip scheduled blood tests. Worsening bilirubin or transaminases may require prompt specialist assessment and holding or discontinuing treatment under the prescribing information [10][8].
With consistent treatment and monitoring, many children with CBAS1 lead healthy, active lives, potentially avoiding the need for a liver transplant [1][11].
Common questions in this guide
What medicine is usually used to treat CBAS1?
How does cholic acid protect my child’s liver?
How is the cholic acid dose decided, and what if a dose is missed?
Will my child need vitamins while taking cholic acid?
Which tests are used to monitor cholic acid treatment?
What side effects or warning signs should I report?
Can cholic acid help my child avoid a liver transplant?
Get notified when new evidence is published on Congenital bile acid synthesis defect type 1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (11)
- 1
Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood.
Gonzales E, Matarazzo L, Franchi-Abella S, et al.
Orphanet journal of rare diseases 2018; (13(1)):190 doi:10.1186/s13023-018-0920-5.
PMID: 30373615 - 2
Open-label Phase 3 Continuation Study of Cholic Acid in Patients With Inborn Errors of Bile Acid Synthesis.
Heubi JE, Setchell KDR
Journal of pediatric gastroenterology and nutrition 2020; (70(4)):423-429 doi:10.1097/MPG.0000000000002618.
PMID: 31899729 - 3
Substrate specificity and kinetic mechanism of 3β-hydroxy-Δ5-C27-steroid oxidoreductase.
Gardner SM, Vogt A, Penning TM, Marmorstein R
The Journal of biological chemistry 2024; (300(12)):107945 doi:10.1016/j.jbc.2024.107945.
PMID: 39505210 - 4
Tandem mass spectrometric determination of atypical 3β-hydroxy-Δ5-bile acids in patients with 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency: application to diagnosis and monitoring of bile acid therapeutic response.
Zhang W, Jha P, Wolfe B, et al.
Clinical chemistry 2015; (61(7)):955-63 doi:10.1373/clinchem.2015.238238.
PMID: 25931455 - 5
Oral Cholic Acid Is Efficacious and Well Tolerated in Patients With Bile Acid Synthesis and Zellweger Spectrum Disorders.
Heubi JE, Bove KE, Setchell KDR
Journal of pediatric gastroenterology and nutrition 2017; (65(3)):321-326 doi:10.1097/MPG.0000000000001657.
PMID: 28644367 - 6
[Infant with 3β-hydroxy-Δ(5)-C27 steroid dehydrogenase deficiency: report of two cases and literatures review].
Li X, Huang Z, Wang H
Zhonghua er ke za zhi = Chinese journal of pediatrics 2015; (53(5)):360-5.
PMID: 26080666 - 7
Bile Acid Synthesis Disorder Masquerading as Intractable Vitamin D-Deficiency Rickets.
Ahmad O, Nogueira J, Heubi JE, et al.
Journal of the Endocrine Society 2019; (3(2)):397-402 doi:10.1210/js.2018-00314.
PMID: 30746501 - 8
Bile Acid Synthesis Disorders in Arabs: A 10-year Screening Study.
Al-Hussaini AA, Setchell KDR, AlSaleem B, et al.
Journal of pediatric gastroenterology and nutrition 2017; (65(6)):613-620 doi:10.1097/MPG.0000000000001734.
PMID: 28902093 - 9
Delayed diagnosis of 3β-HSD7 deficiency in adolescence: Two case reports and review of the literature.
Pendleton S, Mostafavi M, Mathew J, et al.
JPGN reports 2026; (7(2)):236-241 doi:10.1002/jpr3.70159.
PMID: 42110141 - 10
Cholic acid therapy in Zellweger spectrum disorders.
Berendse K, Klouwer FC, Koot BG, et al.
Journal of inherited metabolic disease 2016; (39(6)):859-868 doi:10.1007/s10545-016-9962-9.
PMID: 27469511 - 11
Atypical clinical presentation and successful treatment with oral cholic acid of a child with defective bile acid synthesis due to a novel mutation in the HSD3B7 gene.
Bossi G, Giordano G, Rispoli GA, et al.
Pediatric reports 2017; (9(3)):7266 doi:10.4081/pr.2017.7266.
PMID: 29081931
This page explains cholic acid treatment, vitamin support, and monitoring for a child with CBAS1 for informational purposes only and does not constitute medical advice. Your child’s prescribing specialist should determine the dose, supplements, and response to any abnormal test result.